EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Gelteq Limited (GELS) fair value: what the stock is really worth

We calculate from audited financials what Gelteq Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Australia · ISIN AU0000218109

GL Gelteq Limited logo Thin data Jul 24, 2026

Gelteq Limited

GELS · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $0.6900 · Undervalued (+15%)
!Quality 26/100
!Mixed Growth (revenue 3y +3.9 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (4/8)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Gelteq Limited Ordinary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.79 $0.3900 Fair Value $0.6900 Oct 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

23‑month range $0.3900 – $4.79 · fair‑value band $0.5100 – $1.03 · the $0.6009 price screens below the $0.6900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.

Follow Gelteq Limited Ordinary Shares in your weekly email

Every Wednesday you see whether Gelteq Limited Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.

Show more

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Stock analysis

Gelteq Limited Ordinary Shares (GELS) currently trades at $0.6009, while our model-based Fair Value estimate is $0.6900, implying the stock looks roughly 12.9% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.

Scenario range: $0.5100 (bear) to $1.03 (bull), the price of $0.6009 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Gelteq Limited Ordinary Shares reported revenue of A$166K in FY2025 versus A$0 in FY2021. Reported net income was −A$6.6M in FY2025.

Key figures

Market cap $11.1M · P/S ratio 27.0 · EPS (TTM) $−0.5100 · Return on equity −43.0% · Return on assets (EBIT) −14.0% · Operating margin −2,969% · Revenue (TTM) A$413K · Revenue growth (YoY) +59.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 54% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 15%, GELS screens cheaper than that median.

Fair Value models

Bear $0.5100 Fair Value $0.6900 Bull $1.03
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.7400 $0.9900 $1.48 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.7400 $0.9900 $1.48 54

Open the full fair value analysis →

Notify me when GELS reaches fair value

Put GELS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 28 · Market factors (momentum, volatility) 9

Profitability 0
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 48
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 1/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch GELS, get fair value alerts →

Compare Gelteq Limited Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +15% · Above median
Profitability
Return on assets −15% · Bottom 25%
Growth and dividend
Revenue growth 59% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.70× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 26.96× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)53 · sector 14
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gelteq Limited Ordinary Shares · Fair Value
$0.6900 +13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Gelteq Limited Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/GELS

Frequently asked questions

Is Gelteq Limited (GELS) overvalued or undervalued?
As of Jul 24, 2026, our model estimates a fair value of $0.6900 versus a price of $0.6009, about +15% upside (undervalued).
What is the fair value of GELS?
Our model-based fair value for Gelteq Limited Ordinary Shares is $0.6900 (as of Jul 24, 2026), built from audited fundamentals. The current price: $0.6009.
What is the quality score of GELS?
Gelteq Limited Ordinary Shares has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gelteq Limited (GELS)?
Our model-based price target is the fair value of $0.6900 (as of Jul 24, 2026) from 1 valuation models. Cautious scenario $0.5100, optimistic scenario $1.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Gelteq Limited Ordinary Shares stock forecast for 2026?
Our models put fair value at $0.6900, about +15% upside versus a price of $0.6009 (undervalued). Cautious scenario $0.5100, optimistic scenario $1.03. The calculation is refreshed regularly with new filings.
What is the revenue of Gelteq Limited (GELS)?
Gelteq Limited Ordinary Shares reported trailing-twelve-month revenue of about A$413K (latest available figure, as of Jul 24, 2026).
What is the intrinsic value of Gelteq Limited (GELS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gelteq Limited Ordinary Shares it is $0.6900 per share (as of Jul 24, 2026), against a price of $0.6009. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Gelteq Limited Ordinary Shares stock overvalued or undervalued in 2026?
As of Jul 24, 2026, GELS trades below its calculated fair value: price $0.6009, fair value $0.6900, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GELS?
No. The price is what the market pays today ($0.6009); the fair value is what the company's own numbers justify ($0.6900). For Gelteq Limited Ordinary Shares the two are $0.0891 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gelteq Limited Ordinary Shares worth?
The market values Gelteq Limited Ordinary Shares at about $11.1M (market capitalisation, as of Jul 24, 2026). Per share that is $0.6009; our models calculate a fair value of $0.6900 per share.
What do the bullish and bearish scenarios say about GELS?
Our models span a range for Gelteq Limited Ordinary Shares: cautious scenario $0.5100, base $0.6900, optimistic $1.03 per share (as of Jul 24, 2026, price $0.6009). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gelteq Limited (GELS)?
Balance-sheet figures for Gelteq Limited Ordinary Shares (as of Jul 24, 2026): return on equity −43.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is GELS from its 52-week high?
Gelteq Limited Ordinary Shares trades at $0.6009, about 61% below its 52-week high of $1.53 and 54% above the low of $0.3900 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6900 is for.
Which stocks are comparable to Gelteq Limited Ordinary Shares?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gelteq Limited Ordinary Shares stock attractive at the current price?
The data as of Jul 24, 2026: price $0.6009, calculated fair value $0.6900 (+15%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GELS calculated?
We run Gelteq Limited Ordinary Shares through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Gelteq Limited Ordinary Shares currently trades 15 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gelteq Limited (GELS)?
The closing price on Sep 23, 2026 was $0.6009. Our model-based fair value is $0.6900, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gelteq Limited Ordinary Shares right now?
A fairly wide model range ($0.5100 to $1.03) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Gelteq Limited Ordinary Shares

How large is the market capitalisation of Gelteq Limited (GELS)?
The market capitalisation of Gelteq Limited Ordinary Shares is $11.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gelteq Limited (GELS)?
The price-to-sales ratio of Gelteq Limited Ordinary Shares is 27.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gelteq Limited (GELS)?
Earnings per share at Gelteq Limited Ordinary Shares are $−0.5100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Gelteq Limited (GELS)?
The return on equity (ROE) of Gelteq Limited Ordinary Shares is −43.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gelteq Limited (GELS)?
On an EBIT basis the return on assets of Gelteq Limited Ordinary Shares is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gelteq Limited (GELS)?
The operating margin of Gelteq Limited Ordinary Shares is −2,969% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gelteq Limited (GELS)?
Revenue at Gelteq Limited Ordinary Shares is growing +59.4% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Gelteq Limited (GELS) generate?
The free cash flow of Gelteq Limited Ordinary Shares is −A$6.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gelteq Limited (GELS) carry?
The net debt of Gelteq Limited Ordinary Shares is A$3.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Gelteq Limited Ordinary Shares in the live analysis

One click puts Gelteq Limited Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.